Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.
View Top Employees from AffyImmune Therapeutics| Website | https://affyimmune.com/ |
| Employees | 36 (36 on RocketReach) |
| Founded | 2016 |
| Address | 22 Strathmore Rd, Natick, Massachusetts 01760, US |
| Technologies |
JavaScript,
HTML,
PHP
+15 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals |
Looking for a particular AffyImmune Therapeutics employee's phone or email?
AffyImmune Therapeutics Questions
Sonal Kothari-Gupta is the Senior Vice President, Head of Clinical Development of AffyImmune Therapeutics.
36 people are employed at AffyImmune Therapeutics.
AffyImmune Therapeutics is based in Natick, Massachusetts.
Top AffyImmune Therapeutics Employees
-
55+
-
-
View
Alyssa Birt
Associate Director, Preclinical Development at AffyImmune Therapeutics
Northborough, MA, US25+ -
31
-
21
-
12
Related Companies
